
On-Demand Content | Virtual Event

Carve-outs, estoppel, restrictions on venue, and ANDA litigation remain some of the hottest contested issues under Paragraph IV of the Hatch-Waxman Act. Via Momentum’s fully interactive platform, join us as our conference faculty of esteemed judges, leading in-house counsel and experienced practitioners provide you with the tactics, tools, strategies and insight you need when litigating Paragraph IV cases.
SPEAKER HIGHLIGHTS
Top Reasons to Purchase
- Obtain the thoughts of Federal Circuit and PTAB Judges regarding to best practices when arguing a case related to pharmaceutical IP
- Put the outcomes of “GSK v. Teva” and “Minerva Surgical v Hologic Inc” into use as you prepare for upcoming Paragraph IV litigation
- Strengthen your abilities to protect company intellectual property overseas by examining current international regulations and court rulings
- Further understand how President Biden’s potential waiver in the fight against COVID-19 may affect the IP rights of pharmaceuticals and biologics going forward
- Network with leading Paragraph IV experts to ready yourself for future litigation
Who Should Purchase
Professionals from Pharmaceutical and Medical Device Companies with Titles Including:
- Associate General Counsel, Litigation
- Associate General Counsel, IP
- Patent Counsel
- Senior Legal Counsel
- Vice-President, Intellectual Property
- Director, Intellectual Property
- General Counsel
- Head of Intellectual Property
On-Demand Content
$195
Continuing Legal Education credits (CLE) offered at this event. For more information, click here
